|
Post by yossarian on Mar 27, 2015 7:08:29 GMT -5
Note this info. from a webposting published: Thursday, 23 October 2014 20:57 Written by Dr. Hung V Tran, M.D., M.S. From: www.retailinvestor360.com/educational/658-corporate-versus-non-corporate-partnerships-joint-ventures-merger-and-acquisitions-and-mannkind-s-affairs.html#.VRVEFPjqY34.twitter MannKind-Sanofi Partnership to M&A The market has been speculating, as to whether the MannKind-Sanofi partnership will lead to a full-blown merger and acquisition. Corporate filings with the U.S. Patent Trade Office revealed MannKind transferred Afrezza’s patent and the firm’s interest to Aventisub LLC, an asset holding company formed by Sanofi, on September 29, 2014. The aberrant after hour transactions in the past month, where large blocks of MannKind common shares traded, also raised further questions by shareholders. MannKind’s corporate headquarter in Valencia, California, has also been listed for sales further evidencing an incoming M&A. But that’s not all. CEO and Founder Mann founded more than 17 biotech companies and sold them at significant premiums. Mann is similar to, “The Most Interesting Man in the World” to say the least. There are speculations as to whether Mann is taking a private company, “Second Sight,” to IPO. Like they said, it’s tought for a man to break his habits. * * * * * In a reasonable explanation, Sanofi is waiting for Afrezza to substantiate sales—ensuring the novel inhaled Technosphere Insulin will not flop in the market like Exubera—by then, the French Global Diabetes leader will jump in with both feet. Perhaps, that explains large blocks of MannKind stock after hour’s transactions: The lesson learned from Pfizer’s mistake of “testing the water with both feet,” in 2006, is still fresh in the biopharma space. Notwithstanding, speculations are still guessing games. What is certain, the partnership infused MannKind with $150million upfront payment out of the total $1.1billion available. MannKind can now leverage its partner’s elite sales and marketing force of more than 35,000 professionals, to deliver its much-needed flagship product Afrezza to million of patients suffering from diabetes world wide.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Mar 27, 2015 8:48:54 GMT -5
Note this info. from a webposting published: Thursday, 23 October 2014 20:57 Written by Dr. Hung V Tran, M.D., M.S. From: www.retailinvestor360.com/educational/658-corporate-versus-non-corporate-partnerships-joint-ventures-merger-and-acquisitions-and-mannkind-s-affairs.html#.VRVEFPjqY34.twitter MannKind-Sanofi Partnership to M&A The market has been speculating, as to whether the MannKind-Sanofi partnership will lead to a full-blown merger and acquisition. Corporate filings with the U.S. Patent Trade Office revealed MannKind transferred Afrezza’s patent and the firm’s interest to Aventisub LLC, an asset holding company formed by Sanofi, on September 29, 2014. The aberrant after hour transactions in the past month, where large blocks of MannKind common shares traded, also raised further questions by shareholders. MannKind’s corporate headquarter in Valencia, California, has also been listed for sales further evidencing an incoming M&A. But that’s not all. CEO and Founder Mann founded more than 17 biotech companies and sold them at significant premiums. Mann is similar to, “The Most Interesting Man in the World” to say the least. There are speculations as to whether Mann is taking a private company, “Second Sight,” to IPO. Like they said, it’s tought for a man to break his habits. * * * * * In a reasonable explanation, Sanofi is waiting for Afrezza to substantiate sales—ensuring the novel inhaled Technosphere Insulin will not flop in the market like Exubera—by then, the French Global Diabetes leader will jump in with both feet. Perhaps, that explains large blocks of MannKind stock after hour’s transactions: The lesson learned from Pfizer’s mistake of “testing the water with both feet,” in 2006, is still fresh in the biopharma space. Notwithstanding, speculations are still guessing games. What is certain, the partnership infused MannKind with $150million upfront payment out of the total $1.1billion available. MannKind can now leverage its partner’s elite sales and marketing force of more than 35,000 professionals, to deliver its much-needed flagship product Afrezza to million of patients suffering from diabetes world wide. please dont bring that Tran spam here lol
|
|
|
Post by yossarian on Mar 27, 2015 11:00:50 GMT -5
Is his information false?
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Mar 27, 2015 11:31:52 GMT -5
Is his information false? even a broken clock would not be right twice in his case and similar to sierra world equity..
|
|
|
Post by robsacher on Mar 27, 2015 14:01:45 GMT -5
I would be surprised if MannKind is going to be sold as they are placing much energy into finding new drugs for Technosphere. If anything was sold, it would have been Afrezza to Sanofi, before a licensing deal was worked out.
|
|
|
Post by bradleysbest on Mar 27, 2015 14:32:04 GMT -5
Agree as TS is the real prize!
|
|
|
Post by BlueCat on Mar 27, 2015 22:34:58 GMT -5
I still think there is a reasonable business argument to suggest that if this is a global blockbuster, that 35% profit will be worth some bank to SNY.
And indeed, as it takes off, so will the cost of buying just Afrezza, or the whole Technosphere kitchen sink if deals are now announced too.
However:
1. SNY is under pressure with their diabetes business - revenue may be challenged with Lantus, etc.
2. Under pressure, they may not want to spend resources on acquiring a drug or company in a battleground stock, that is making its first appearance on the market and by most accounts, is waiting to be market-proven (already medically-proven)
3. They do need to focus energy on Touejo. They must do all the heavy lifting there, and they really need that to be successful.
4. They have a functioning agreement/relationship with MNKD. (aka: its not broken at moment. Do they really need to fix it?)
5. At moment, they are paying the costs to launch the thing - which they would have to pay even with BO, and because not enough profit has been gained to worry about losing that 35%, they haven't really lost anything - yet. And with an intent of slow ramp - they have a little time until wishing they kept the 35% would be the case.
Even if bullish posters here, MNKD and SNY all believe Afrezza will go global blockbuster, the financial community has clearly mixed views and big or positive announcements don't have exactly a positive impact on MNKD stock price.
So - What would it do to SNY stock if they announced a BO today? My guess is it would take a mega hit. AF, GS, and the usuals would then initiate a major short on SNY, and then follow-up with all the bashing articles to drive down. Imagine the headlines ... "Exubera Karma - What goes around comes around. Sanofi now duped just like Pfizer with failing MannKind and Afrezza"
Maybe, just maybe, they really do have to wait on this. Perhaps time is money - they are willing to have to pay a bit more later, to not have to act now. No matter how much my stock account wishes they would have acted last summer ....
|
|
|
Post by BlueCat on Mar 27, 2015 22:43:34 GMT -5
Add on this comes up after they dismissed the last CEO, followed by charges of questionable practices, and a shake up of the US team.
Even if the actual $ are a drop in the bucket, there is a perception issue, and they may want to the dust to settle a bit first.
|
|
|
Post by rak5555 on Mar 28, 2015 12:25:24 GMT -5
I have 3 thoughts about M&A:
1) I agree that SNY will wait until they substantiate the market potential of Afrezza before entertaining a buyout; however, they will have the insight to know the market potential of Afrezza way before the rest of us. Its not just sales, but sales relative to effort. For example, not only do they know how many sample packs are being distributed, they know the conversion rate from samples to scripts. 2) Recently, SNY has shown that it first takes a position in partner's stock, then gradually adds. Certainly this is cheaper than announcing a buyout price for 100% of the shares. Better to buy first 10, 20, xx% at discount, then announce buyout. 3) Once SNY realizes the true global potential of Afrezza, they will not want to entrust manufacturing to a small company with absolutely zero global manufacturing experience. Solution to this risk = buyout of MNKD or at least all things Afrezza (and future TI diabetes applications).
PS: I typed this post while driving my car.
|
|
|
Post by gamblerjag on Mar 28, 2015 12:38:47 GMT -5
Rak... good post.. but man... not while driving.. your gonna kill yourself and not see the green in your investment.
|
|
|
Post by als57 on Mar 28, 2015 12:44:52 GMT -5
Rak: If you continue typing while driving, there is a religious experience in your near-term future! Please, eyes on the road.
|
|
|
Post by mnholdem on Mar 28, 2015 13:37:56 GMT -5
Rak,
Re #3 - Sanofi already secured rights in the Agreement to manufacture Afrezza, which is essential for meeting global demand, so I wouldn't list that as a BO reason, IMHO.
...and texting while driving is strongly encouraged in the state of Wisconsin, to help thin out the Packer population. Note that this is the state that recently made it legal to hunt & kill stray cats. "Meow?"...BANG!
Good fortune all.
|
|
|
Post by babaoriley on Mar 28, 2015 16:02:06 GMT -5
I believe rak was joking about typing that while driving. He's got enough money to spend for at least 40 more years, so he's not going to miss out on that extravaganza!
Of course, he may have been "driving" it through a car wash.
|
|
|
Post by afrizzle on Mar 28, 2015 18:03:06 GMT -5
There is an unfortunate typo in one off his two points. Did he mean "sale" in the singular form or "sales" as written. I can't find any evidenced that the facility is up for sale. If your google the address there is some old preview cache that does say "for lease" However after the Herculean effort of an additional click, Loopnet (the zillow of the commercial space) indicates it's not for sale or lease.
|
|
|
Post by spiro on Mar 28, 2015 20:31:25 GMT -5
Rak could have been driving a dump truck, bulldozer or an automobile. I hope it was the auto.
|
|